July. 11, 2018 - "In Q2 18 Orexo delivered one of the best quarters ever"
JULY 11, 2018 For Q2 18 Orexo delivered one of the best quarters ever in terms of net revenue growth of 25 percent and EBITDA of SEK 51 m. The strong Zubsolv US growth of 20 percent was the main driver. The pipeline is about to advance when OX124 will start phase 1 studies later this year.
In conjunction with the publishing of the Q2 18 Interim report, Orexo are introducing “Orexo – our view”, where the aim is to share video comments related to our business. First out is Nikolaj Sørensen, CEO, who for a little more than 3 minutes will comment on the latest development in Q2 18.
Orexo´s pipeline contains projects in different development phases, with a primary therapeutic focus around addiction in all phases, from prevention to treatment. One objective is to increase the pipeline with clinical stage projects. Read more about the development projects below.
As the EU Directive, MiFID II, makes it harder for investors to get analyst reports from banks and brokerage firms… https://t.co/sJ9yfGYQ4q